Filter
3121
Text search:
adverse
health
effects
Featured
Recommendations
340
New Publications
754
Language
Document type
No document type
1636
Studies & Reports
535
Guidelines
534
Manuals
180
Strategic & Response Plan
101
Fact sheets
56
Training Material
45
Situation Updates
13
Infographics
7
Brochures
6
Resource Platforms
5
Videos
2
App
1
Countries / Regions
India
148
Global
136
Kenya
75
Western and Central Europe
72
South Africa
64
Ethiopia
61
Nepal
52
Uganda
51
Nigeria
47
Tanzania
41
Latin America and the Carribbean
40
Africa
39
Sierra Leone
37
Ghana
37
Zambia
35
Malawi
31
Philippines
29
Liberia
28
Myanmar / Burma
28
Bangladesh
27
Rwanda
23
Ukraine
23
South–East Asia Region
21
Zimbabwe
20
Namibia
19
Eastern Europe
19
Syria
18
Cambodia
17
Indonesia
15
East and Southern Africa
14
Asia
14
USA
12
Brazil
12
Guinea
11
South Sudan
11
Botswana
11
Eastern Europe and Central Asia
11
Senegal
10
Germany
10
Eswatini/ Swaziland
10
Congo, Democratic Republic of
9
Mozambique
9
Sudan
9
West and Central Africa
9
Middle East and North Africa
9
Russia
9
Thailand
8
Lesotho
8
Western Pacific Region
8
Burkina Faso
7
Yemen
6
Venezuela
6
Pakistan
5
Colombia
5
Moldova
5
Mali
4
Jordan
4
Afghanistan
4
China
4
Sri Lanka
4
Cameroon
3
Niger
3
Haiti
3
Somalia
3
Lebanon
3
Egypt
3
Madagascar
3
Laos
3
Iraq
2
Gambia
2
Singapore
2
Benin
2
Central African Republic
2
Argentina
2
North Macedonia
2
Ecuador
2
Angola
2
Chile
2
Paraguay
2
Palestine
2
Timor Leste/ East Timor
2
Tajikistan
2
Kyrgyzstan
2
Georgia
2
Vietnam
2
North America
2
Belarus
2
Guinea-Bissau
1
Côte d’Ivoire / Ivory Coast
1
Chad
1
Mauritania
1
Ireland
1
Papua New Guinea
1
Vanuatu
1
Peru
1
Burundi
1
Honduras
1
El Salvador
1
Greece
1
Guatemala
1
Other region
1
Fiji
1
Solomon Islands
1
Bhutan
1
Poland
1
Albania
1
Djibouti
1
Canada
1
Romania
1
Lithuania
1
Iran
1
Kazakhstan
1
Turkmenistan
1
United Kingdom
1
Spain
1
Authors & Publishers
Publication Years
Category
Countries
949
Clinical Guidelines
346
Public Health
182
Women & Child Health
182
Key Resources
171
Capacity Building
46
Pharmacy & Technologies
29
Toolboxes
Mental Health
349
COVID-19
244
TB
200
HIV
193
Planetary Health
181
Pharmacy
102
NTDs
101
NCDs
95
AMR
82
Caregiver
80
Ebola & Marburg
62
Conflict
62
Global Health Education
60
Refugee
53
Disability
48
Rapid Response
45
Malaria
44
Specific Hazards
37
Natural Hazards
35
2.0 Rapid Response
29
Zika
22
Health Financing Toolbox
20
Polio
14
Cholera
10
Social Ethics
5
Typhoon
2
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This Poster is available in English, French, Spanish, Russian, Chinese, Portuguese, Hausa and Arabic
Rapid review and case studies from Member States
Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug treatment be continued after remission in order to allow for the best outcomes?
[Updated 2015]
Scoping Question: In adults with acute convulsive seizures in first-level care or in the community (when no IV access is available), which antiepileptic medications produce benefits and/or harm when compared to comparator?
The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug
...
Q 3: Is brief, structured psychological treatment in non-specialist health care settings better (more effective than/as safe as) than treatment as usual in people with depressive episode/disorder?
Q6: Is advice on physical activity better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder with inactive lifestyles
Physical and social distancing measures are associated with limiting contact between people during disease outbreaks. These measures when applied are often enhanced by lockdowns or shutdowns as part of broader risk communication and community engagement strategies to halt the transmission of disease
...
Q 12: In children and adolescents with anxiety disorders, what is the effectiveness and safety, considering system issues in low- and middle-income countries, of using pharmacological interventions in non-specialist settings?
Second-generation antipsychotic medications for psychotic disorders (including schizophrenia)
recommended
Q14. SCOPING QUESTION: In adults with psychotic disorders (including schizophrenia), what is the comparative effectiveness and safety of second-generation antipsychotic medications?
Understanding and building resilience to early life trauma in Belarus and Ukraine
In 2018 and early 2019, the WHO Regional Office for Europe’s cultural contexts of health and well-being project worked alongside the University of Exeter’s WHO Co
...
A tool for measuring alcohol policy implementation
Q10: Are antidepressants (Tricyclic antidepressants (TCA), Selective serotonin reuptake inhibitors (SSRIs)) effective and safe in children 6-12 years of age with depressive episode/disorder?
Q 4: Is behavioural activation better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?brief, structured psychological treatment in non-specialist health care settings better (more effective than/as
...
Q2: For people with dementia, does memantine, when compared to placebo/comparator, produce benefits/harm in the specified outcomes in non-specialist health settings?
Mental Health First Aid Guidelines
Accessed: 14.03.2019
Accessed: 21.03.2019